
UNITED GUARDIAN INC
UGNASDAQTrading Snapshot
- Day Range
- $7.04 β $7.20
- 52-Week Range
- $5.58 β $8.78
- Volume
- $3.56B
- Avg Volume
- $3.87B
- Shares Outstanding
- 4.6M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $3M
- P/E Ratio
- 14.4
- P/S Ratio
- 3.1x
- EPS (TTM)
- $0.51
- Dividend Yield
- 6.78%
Why Investors Own UG
- βHigh-growth profile β revenue up +45.1% YoY with expanding US Equity exposure.
- βHealthy economics β 44% gross margin and 22% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About UNITED GUARDIAN INC
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
UNITED GUARDIAN INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift UG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
UNITED GUARDIAN INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.